Atypical presentation is the most common form of celiac disease (CD). Although the terminologies like latent, silent and potential have expressed different aspects of clinical and pathological behaviour of CD, they also have contributed in some extent to confusion between clinicians and patients due to the multiple definitions and uncertainty around them. In the light of new advances and the discovery of entities such as non-celiac gluten sensitivity, using subclinical instead of silent and atypical instead of potential/latent may simplify the understanding behind the clinical behaviour of atypical CD. The evidence behind a lower threshold for starting a gluten free diet (GFD) in non-celiac gluten sensitive patients would strongly support applying a GFD treatment strategy in any forms of CD.
Introduction

1
Using multiple terminology in defining atypical celiac disease (CD) has confused many of the clinicians to recognise atypical forms of this common disorder. CD is not considered an uncommon disorder any longer and is not a disease of essentially European origin (1) 
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Microscopic enteritis
The 
Gluten sensitivity and Celiac disease
Gluten sensitivity (GS) is characterised by negative antibodies and normal histology; it is defined as a non-allergic and non-autoimmune condition in which the consumption of gluten can lead to symptoms similar to those seen in CD. Until recently the terms GS and CD were used synonymously in literature (33) and it is not clear yet whether patients affected by GS will have some subtle intestinal and mucosal changes consistent with microscopic
enteritis. Yet we know very little about the pathogenic mechanism behind gluten sensitivity.
Some GS patients would tolerate even more than 5g
gluten/day and still remain symptom free with negative serology (34, 35) . On the other hand around 50% of the GS patients were DQ2/DQ8 positive, which is similar to that of the general population, while celiac patients carry more than 95% in most regions of the word.
However, while the prevalence of CD is roughly 1%
within the general population, GS is thought to affect 6 to 10% of the general population (37 
Conclusion
The spectrum of gluten related disorders is widening. This is because these common systemic disorders have multifactorial etiology with a multitude of symptoms and complications inside and outside the small bowel. We still don't know how seriously subclinical CD will be affected by the long term complications if they are not treated with GFD.
A marked increase in the prevalence of CD, especially the subclinical CD forms and non-celiac gluten sensitivity, seem to become a major health problem (43) (44) (45) (46) . The clinician may often face the variability of histological and clinical aspects of CD (46) with uncertainty, as they might not quite fit into the diagnostic models in the current guidelines.
Accumulated evidence supports that decreasing the treatment threshold for cases with atypical CD and those with gluten sensitivity, as the life quality of these cases will improve with GFD and the longterm health benefit of this strategy, would perhaps be also cost effective.
